Effect of Mobile Device-Assisted N-of-1 Trial Participation on Analgesic Prescribing for Chronic Pain: Randomized Controlled Trial

Objectives Opioids and non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed for chronic musculoskeletal pain, despite limited evidence of effectiveness and well-documented adverse effects. We assessed the effects of participating in a structured, personalized self-experiment (“N-of-1 trial”) on analgesic prescribing in patients with chronic musculoskeletal pain. Methods We randomized 215 patients with chronic pain to participate in an N-of-1 trial facilitated by a mobile health app or to receive usual care. Medical records of participating patients were reviewed at enrollment and 6 months later to assess analgesic prescribing. We established thresholds of ≥ 50, ≥ 20, and > 0 morphine milligram equivalents (MMEs) per day to capture patients taking relatively high doses only, patients taking low-moderate as well as relatively high doses, and patients taking any dose of opioids, respectively. Results There was no significant difference between the N-of-1 and control groups in the percentage of patients prescribed any opioids (relative odds ratio (ROR) = 1.05; 95% confidence interval [CI] = 0.61 to 1.80, p  = 0.87). There was a clinically substantial but statistically not significant reduction of the percentage of patients receiving ≥ 20 MME (ROR = 0.58; 95% CI = 0.33 to 1.04, p  = 0.07) and also in the percentage receiving ≥ 50 MME (ROR = 0.50; 95% CI = 0.19 to 1.34, p  = 0.17). There was a significant reduction in the proportion of patients in the N-of-1 group prescribed NSAIDs compared with control (relative odds ratio = 0.53; 95% CI = 0.29 to 0.96, p  = 0.04), with no concomitant increase in average pain intensity. There was no significant change in use of adjunctive medications (acetaminophen, gabapentenoids, or topicals). Discussion These exploratory results suggest that participation in N-of-1 trials may reduce long-term use of NSAIDs; there is also a weak signal for an effect on use of opioids. Additional research is needed to confirm these results and elucidate possible mechanisms. Trial Registration ClinicalTrials.gov Identifier: NCT02116621.

[1]  M S Davis,et al.  Variations in patients' compliance with doctors' advice: an empirical analysis of patterns o communication. , 1968, American journal of public health and the nation's health.

[2]  Statistical decision theory and clinical trials. , 1982, British journal of clinical pharmacology.

[3]  S. Kaplan,et al.  Expanding patient involvement in care. Effects on patient outcomes. , 1985, Annals of internal medicine.

[4]  John E. Ware,et al.  Expanding Patient Involvement in Care , 1985 .

[5]  C. Huerta,et al.  Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  J. Brophy,et al.  Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. , 2006, American journal of epidemiology.

[7]  C. Schmid,et al.  Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. , 2006, The Journal of rheumatology.

[8]  M. Tonelli,et al.  NSAID use and progression of chronic kidney disease. , 2007, The American journal of medicine.

[9]  P. Ubel,et al.  Mispredictions and misrecollections: Challenges for subjective outcome measurement , 2008, Disability and rehabilitation.

[10]  C. Rutter,et al.  De Facto Long-term Opioid Therapy for Noncancer Pain , 2008, The Clinical journal of pain.

[11]  Bradley C. Martin,et al.  Trends in use of opioids for non-cancer pain conditions 2000–2005 in Commercial and Medicaid insurance plans: The TROUP study , 2008, PAIN.

[12]  S. Asch,et al.  Development and Initial Validation of the PEG, a Three-item Scale Assessing Pain Intensity and Interference , 2009, Journal of General Internal Medicine.

[13]  C. Rutter,et al.  Trends in long‐term opioid therapy for chronic non‐cancer pain , 2009, Pharmacoepidemiology and drug safety.

[14]  M. Egger,et al.  Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis , 2011, BMJ : British Medical Journal.

[15]  A. Zautra,et al.  Socioeconomic disparities in pain: the role of economic hardship and daily financial worry. , 2011, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[16]  R. Labianca,et al.  Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. , 2012, Clinical drug investigation.

[17]  R. Labianca,et al.  Adverse Effects Associated with Non-opioid and Opioid Treatment in Patients with Chronic Pain , 2012, Clinical Drug Investigation.

[18]  M. Wehling.  Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects , 2014, European Journal of Clinical Pharmacology.

[19]  R. Kravitz.  Personalized Medicine Without the “Omics” , 2014, Journal of general internal medicine.

[20]  M. Castell,et al.  Self-perceived weather sensitivity and joint pain in older people with osteoarthritis in six European countries: results from the European Project on OSteoArthritis (EPOSA) , 2013, BMC Musculoskeletal Disorders.

[21]  W. Häuser,et al.  Opioide bei chronischen nicht-tumorbedingten Schmerzen – sind sie Nichtopioidanalgetika überlegen? , 2015, Der Schmerz.

[22]  R. Kravitz,et al.  The PREEMPT study - evaluating smartphone-assisted n-of-1 trials in patients with chronic pain: study protocol for a randomized controlled trial , 2015, Trials.

[23]  S. Straube,et al.  Overview review: Comparative efficacy of oral ibuprofen and paracetamol (acetaminophen) across acute and chronic pain conditions , 2015, European journal of pain.

[24]  C. Schmid,et al.  Comparative Effectiveness of Pharmacologic Interventions for Knee Osteoarthritis , 2015, Annals of Internal Medicine.

[25]  J. Moloo.  Comparative Effectiveness of Pharmacologic Interventions for Knee Osteoarthritis , 2015 .

[26]  M. Castell,et al.  The Influence of Weather Conditions on Joint Pain in Older People with Osteoarthritis: Results from the European Project on OSteoArthritis , 2015, The Journal of Rheumatology.

[27]  Judith H Hibbard,et al.  When patient activation levels change, health outcomes and costs change, too. , 2015, Health affairs.

[28]  R. Chou,et al.  The Effectiveness and Risks of Long-Term Opioid Therapy for Chronic Pain: A Systematic Review for a National Institutes of Health Pathways to Prevention Workshop , 2015, Annals of Internal Medicine.

[29]  Erratum zu: Opioide bei chronischen nicht-tumorbedingten Schmerzen – sind sie Nichtopioidanalgetika überlegen? , 2015, Der Schmerz.

[30]  Christopher M Callahan,et al.  National Institutes of Health Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain , 2015, Annals of Internal Medicine.

[31]  C Sommer,et al.  [Opioids in chronic noncancer pain-are opioids superior to nonopioid analgesics? A systematic review and meta-analysis of efficacy, tolerability and safety in randomized head-to-head comparisons of opioids versus nonopioid analgesics of at least four week's duration]. , 2015, Schmerz.

[32]  Roger Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. , 2016, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[33]  R. Chou,et al.  CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. , 2016, JAMA.

[34]  P. Wiffen,et al.  Topical NSAIDs for chronic musculoskeletal pain in adults. , 2016, The Cochrane database of systematic reviews.

[35]  B. Koes,et al.  Non-steroidal anti-inflammatory drugs for sciatica. , 2016, The Cochrane database of systematic reviews.

[36]  M. Schuemie,et al.  Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study , 2016, British Medical Journal.

[37]  Dan Dediu,et al.  Computation of adherence to medication and visualization of medication histories in R with AdhereR: Towards transparent and reproducible use of electronic healthcare data , 2017, PloS one.

[38]  Joanne L. Jordan,et al.  Effective treatment options for musculoskeletal pain in primary care: A systematic overview of current evidence , 2017, PloS one.

[39]  E. Hawk,et al.  Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic , 2017, Open Heart.

[40]  P. Weeke,et al.  Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case–time–control study , 2016, European heart journal. Cardiovascular pharmacotherapy.

[41]  M. Bhandari,et al.  Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials , 2017, PLoS medicine.

[42]  E. Kalso,et al.  Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews. , 2017, The Cochrane database of systematic reviews.

[43]  J. Brophy,et al.  Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data , 2017, British Medical Journal.

[44]  R. Chou,et al.  Systemic Pharmacologic Therapies for Low Back Pain: A Systematic Review for an American College of Physicians Clinical Practice Guideline , 2017, Annals of Internal Medicine.

[45]  P. Bijur,et al.  Effect of a Single Dose of Oral Opioid and Nonopioid Analgesics on Acute Extremity Pain in the Emergency Department: A Randomized Clinical Trial , 2017, JAMA.

[46]  Randall Young,et al.  Vital Signs: Changes in Opioid Prescribing in the United States, 2006–2015 , 2017, MMWR. Morbidity and mortality weekly report.

[47]  T. Fukui,et al.  Weather and Health Symptoms , 2018, International journal of environmental research and public health.

[48]  W. Schaffner,et al.  Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases , 2018, Annals of Internal Medicine.

[49]  R. Kravitz,et al.  Patient Perceptions of Their Own Data in mHealth Technology–Enabled N-of-1 Trials for Chronic Pain: Qualitative Study , 2018, JMIR mHealth and uHealth.

[50]  M. Brennan,et al.  Reduction of opioid use and improvement in chronic pain in opioid-experienced patients after topical analgesic treatment: an exploratory analysis , 2018, Postgraduate medicine.

[51]  R. Kravitz,et al.  Effect of Mobile Device–Supported Single-Patient Multi-crossover Trials on Treatment of Chronic Musculoskeletal Pain: A Randomized Clinical Trial , 2018, JAMA internal medicine.

[52]  S. Shiffman,et al.  Exceeding the daily dosing limit of nonsteroidal anti‐inflammatory drugs among ibuprofen users , 2018, Pharmacoepidemiology and drug safety.

[53]  K. Kroenke,et al.  Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial , 2018, JAMA.

[54]  F. O’Connor,et al.  Association of Nonsteroidal Anti-inflammatory Drug Prescriptions With Kidney Disease Among Active Young and Middle-aged Adults , 2019, JAMA network open.